Noncoding RNAs in cancer immunology

Advances in Experimental Medicine and Biology

Volumn 927, Issue , 2016, Pages 243-264

  Li, Qian ^a   Liu, Qiang ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Cancer immunology; Long noncoding RNAs; MicroRNAs; Noncoding RNAs

Indexed keywords

FAS AS1 LONG NONCODING RNA; GATA3 AS1 LONG NONCODING RNA; IFNG AS1 LONG NONCODING RNA; LETHE LONG NONCODING RNA; LINCRNA CCR2-5'AS; LINCRNA COX2; LINCRNA MAF 4; LONG NONCODING RNA DENDRITIC CELL; LONG NONCODING RNA INTERLEUKIN 7 RECEPTOR ALPHA SUBUNIT; LONG UNTRANSLATED RNA; MICRORNA; MICRORNA 106A; MICRORNA 146A; MICRORNA 146B; MICRORNA 150; MICRORNA 155; MICRORNA 17-5P; MICRORNA 17-92; MICRORNA 181A; MICRORNA 181B; MICRORNA 20A; NF KAPPA B INTERACTING LONG NONCODING RNA; NONCODING RNA REPRESSOR OF NFAT; P50 ASSOCIATED CYCLOOXYGENASE 2 EXTRAGENIC RNA; TUMOR NECROSIS FACTOR ALPHA AND HETEROGENOUS NUCLEAR RIBONUCLEOPROTEIN L RELATED IMMUNOREGULATORY LINCRNA; UNCLASSIFIED DRUG; UNTRANSLATED RNA;

B LYMPHOCYTE; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CYTOKINE PRODUCTION; HUMAN; IMMUNOSURVEILLANCE; MACROPHAGE; METASTASIS; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; SOLID TUMOR; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR ESCAPE; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; EXOSOME; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; NEOPLASM; PATHOLOGY;

EXOSOMES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; MICRORNAS; NEOPLASMS; RNA, LONG NONCODING; TUMOR MICROENVIRONMENT;

EID: 84982732356     PISSN: 00652598     EISSN: 22148019     Source Type: Book Series    
DOI: 10.1007/978-981-10-1498-7_9     Document Type: Chapter

References (76)

1. Gross L. Intradermal immunization of C3H mice against a sarcoma that originated in an animal of the same line. Cancer Res. 1942;3(5):326-33.
2. Burnet M. Cancer-a biological approach. I. The processes of control. Br Med J. 1957;1(5022):779-86.
3. Mayordomo JI, Zorina T, Storkus WJ, et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med. 1995;1(12):1297-302.
4. Flamand V, Sornasse T, Thielemans K, et al. Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo. Eur J Immunol. 1994;24(3):605-10. doi: 10.1002/eji.1830240317.
5. Celluzzi CM, Mayordomo JI, Storkus WJ, et al. Peptide-pulsed dendritic cells induce antigenspecific CTL-mediated protective tumor immunity. J Exp Med. 1996;183(1):283-7.
6. Brossart P, Wirths S, Brugger W, Kanz L. Dendritic cells in cancer vaccines. Exp Hematol. 2001;29(11):1247-55.
7. Steinman RM, Dhodapkar M. Active immunization against cancer with dendritic cells: the near future. Int J Cancer. 2001;94(4):459-73.
8. Byrne SN, Halliday GM. Dendritic cells: making progress with tumour regression? Immunol Cell Biol. 2002;80(6):520-30. doi: 10.1046/j.1440-1711.2002.01122.x.
9. Parmiani G, Castelli C, Dalerba P, et al. Cancer immunotherapy with peptide-based vaccines: what have we achieved? where are we going? J Natl Cancer Inst. 2002;94(11):805-18.
10. Couzin-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy. Science. 2013;342(6165):1432-3. doi: 10.1126/science.342.6165.1432.
11. Parish CR. Cancer immunotherapy: the past, the present and the future. Immunol Cell Biol. 2003;81(2):106-13. doi: 10.1046/j.0818-9641.2003.01151.x.
12. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol. 2004;22:329-60. doi: 10.1146/annurev.immunol.22.012703.104803.
13. Kim R, Emi M, Tanabe K. Cancer immunoediting from immune surveillance to immune escape. Immunology. 2007;121(1):1-14. doi: 10.1111/j.1365-2567.2007.02587.x.
14. Su S, Liu Q, Chen J, et al. A positive feedback loop between mesenchymal-like cancer cells and macrophages is essential to breast cancer metastasis. Cancer Cell. 2014;25(5):605-20. doi: 10.1016/j.ccr.2014.03.021.
15. Fontana L, Pelosi E, Greco P, et al. MicroRNAs 17-5p-20a-106a control monocytopoiesis through AML1 targeting and M-CSF receptor up-regulation. Nat Cell Biol. 2007;9(7):775-87. doi: 10.1038/ncb1613.
16. Costinean S, Zanesi N, Pekarsky Y, et al. Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in E(mu)-miR155 transgenic mice. Proc Natl Acad Sci U S A. 2006;103(18):7024-9. doi: 10.1073/pnas.0602266103.
17. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006;6(11):857-66. doi: 10.1038/nrc1997.
18. Tili E, Croce CM, Michaille JJ. MiR-155: on the crosstalk between infl ammation and cancer. Int Rev Immunol. 2009;28(5):264-84. doi: 10.1080/08830180903093796.
19. O’Connell RM, Chaudhuri AA, Rao DS, Baltimore D. Inositol phosphatase SHIP1 is a primary target of miR-155. Proc Natl Acad Sci U S A. 2009;106(17):7113-18. doi: 10.1073/pnas.0902636106.
20. O’Connell RM, Taganov KD, Boldin MP, et al. MicroRNA-155 is induced during the macrophage infl ammatory response. Proc Natl Acad Sci U S A. 2007;104(5):1604-9. doi: 10.1073/pnas.0610731104.
21. Androulidaki A, Iliopoulos D, Arranz A, et al. The kinase Akt1 controls macrophage response to lipopolysaccharide by regulating microRNAs. Immunity. 2009;31(2):220-31. doi: 10.1016/j.immuni.2009.06.024.
22. Ceppi M, Pereira PM, Dunand-Sauthier I, et al. MicroRNA-155 modulates the interleukin-1 signaling pathway in activated human monocyte-derived dendritic cells. Proc Natl Acad Sci U S A. 2009;106(8):2735-40. doi: 10.1073/pnas.0811073106.
23. Luers AJ, Loudig OD, Berman JW. MicroRNAs are expressed and processed by human primary macrophages. Cell Immunol. 2010;263(1):1-8. doi: 10.1016/j.cellimm.2010.03.011.
24. Liu G, Friggeri A, Yang Y, et al. MiR-147, a microRNA that is induced upon Toll-like receptor stimulation, regulates murine macrophage infl ammatory responses. Proc Natl Acad Sci U S A. 2009;106(37):15819-24. doi: 10.1073/pnas.0901216106.
25. Tili E, Michaille JJ, Cimino A, et al. Modulation of miR-155 and miR-125b levels following lipopolysaccharide/TNF-alpha stimulation and their possible roles in regulating the response to endotoxin shock. J Immunol. 2007;179(8):5082-9.
26. Sheedy FJ, Palsson-McDermott E, Hennessy EJ, et al. Negative regulation of TLR4 via targeting of the proinfl ammatory tumor suppressor PDCD4 by the microRNA miR-21. Nat Immunol. 2009;11(2):141-7. doi: 10.1038/ni.1828.
27. Zhu D, Pan C, Li L, et al. MicroRNA-17/20a/106a modulate macrophage infl ammatory responses through targeting signal-regulatory protein α. J Allergy Clin Immunol. 2013;132(2):426-36. doi: 10.1016/j.jaci.2013.02.005.
28. Bezman NA, Cedars E, Steiner DF, et al. Distinct requirements of MicroRNAs in NK cell activation, survival, and function. J Immunol. 2010;185(7):3835-46. doi: 10.4049/jimmunol.1000980.
29. Yamanaka Y, Tagawa H, Takahashi N, et al. Aberrant overexpression of microRNAs activate AKT signaling via down-regulation of tumor suppressors in natural killer-cell lymphoma/leukemia. Blood. 2009;114(15):3265-75. doi: 10.1182/blood-2009-06-222794.
30. Bezman NA, Chakraborty T, Bender T, Lanier LL. MiR-150 regulates the development of NK and iNKT cells. J Exp Med. 2011;208(13):2717-31. doi: 10.1084/jem.20111386.
31. Heinemann A, Zhao F, Pechlivanis S, et al. Tumor suppressive microRNAs miR-34a/c control cancer cell expression of ULBP2, a stress-induced ligand of the natural killer cell receptor NKG2D. Cancer Res. 2012;72(2):460-71. doi: 10.1158/0008-5472.CAN-11-1977.
32. Sun JC, Beilke JN, Lanier LL. Adaptive immune features of natural killer cells. Nature. 2009;457(7229):557-61. doi: 10.1038/nature07665.
33. Wu H, Neilson JR, Kumar P, et al. miRNA profiling of naive, effector and memory CD8 T cells. Plos One. 2007;2(10):e1020. doi: 10.1371/journal.pone.0001020.
34. Landgraf P, Rusu M, Sheridan R, et al. A mammalian microRNA expression atlas based on small RNA library sequencing. Cell. 2007;129(7):1401-14. doi: 10.1016/j.cell.2007.04.040.
35. Xu H, Cheung IY, Guo HF, Cheung NK. MicroRNA miR-29 modulates expression of immunoinhibitory molecule B7-H3: Potential implications for immune based therapy of human solid tumors. Cancer Res. 2009;69(15):6275-81. doi: 10.1158/0008-5472.CAN-08-4517.
36. Sheppard HM, Verdon D, Brooks AE, et al. MicroRNA regulation in human CD8+ T cell subsets--cytokine exposure alone drives miR-146a expression. J Transl Med. 2014;12:292. doi: 10.1186/s12967-014-0292-0.
37. Saki N, Abroun S, Soleimani M, et al. The roles of miR-146a in the differentiation of Jurkat T-lymphoblasts. Hematology. 2014;19(3):141-7. doi: 10.1179/1607845413Y.0000000105.
38. Yang L, Boldin MP, Yu Y, et al. MiR-146a controls the resolution of T cell responses in mice. J Exp Med. 2012;209(9):1655-70. doi: 10.1084/jem.20112218.
39. Lu LF, Boldin MP, Chaudhry A, et al. Function of miR-146a in controlling Treg cell-mediated regulation of Th1 responses. Cell. 2010;142(6):914-29. doi: 10.1016/j.cell.2010.08.012.
40. Burger ML, Xue L, Sun Y, et al. Premalignant PTEN-deficient thymocytes activate microRNAs miR-146a and miR-146b as a cellular defense against malignant transformation. Blood. 2014;123(26):4089-100. doi: 10.1182/blood-2013-11-539411.
41. Rodriguez A, Vigorito E, Clare S, et al. Requirement of bic/microRNA-155 for normal immune function. Science. 2007;316(5824):608-11. doi: 10.1126/science.1139253.
42. Banerjee A, Schambach F, DeJong CS, et al. Micro-RNA-155 inhibits IFN-gamma signaling in CD4+ T cells. Eur J Immunol. 2010;40(1):225-31. doi: 10.1002/eji.200939381.
43. Lu LF, Thai TH, Calado DP, et al. Foxp3-dependent microRNA155 confers competitive fitness to regulatory T cells by targeting SOCS1 protein. Immunity. 2008;30(1):80-91. doi: 10.1016/j.immuni.2008.11.010.
44. Zhao XD, Zhang W, Liang HJ, Ji WY. Overexpression of miR-155 promotes proliferation and invasion of human laryngeal squamous cell carcinoma via targeting SOCS1 and STAT3. Plos One. 2013;8(2), e56395. doi: 10.1371/journal.pone.0056395.
45. Li QJ, Chau J, Ebert PJ, et al. MiR-181a is an intrinsic modulator of T cell sensitivity and selection. Cell. 2007;129(1):147-61. doi: 10.1016/j.cell.2007.03.008.
46. Li G, Yu M, Lee WW, et al. Decline in miR-181a expression with age impairs T cell receptor sensitivity by increasing DUSP6 activity. Nat Med. 2012;18(10):1518-24. doi: 10.1038/nm.2963.
47. Nishimura J, Handa R, Yamamoto H, et al. MicroRNA-181a is associated with poor prognosis of colorectal cancer. Oncol Rep. 2012;28(6):2221-6. doi: 10.3892/or.2012.2059.
48. Xiao C, Srinivasan L, Calado DP, et al. Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nat Immunol. 2008;9(4):405-14. doi: 10.1038/ni1575.
49. Sasaki K, Kohanbash G, Hoji A, et al. MiR-17-92 expression in differentiated T cells-implications for cancer immunotherapy. J Transl Med. 2010;8:17. doi: 10.1186/1479-5876-8-17.
50. Taguchi A, Yanagisawa K, Tanaka M, et al. Identification of hypoxia-inducible factor-1 alpha as a novel target for miR-17-92 microRNA cluster. Cancer Res. 2008;68(14):5540-5. doi: 10.1158/0008-5472.CAN-07-6460.
51. Du C, Liu C, Kang J, et al. MicroRNA miR-326 regulates TH-17 differentiation and is associated with the pathogenesis of multiple sclerosis. Nat Immunol. 2009;10(12):1252-9. doi: 10.1038/ni.1798.
52. Hoareau-Aveilla C, Valentin T, Daugrois C, et al. Reversal of microRNA-150 silencing disadvantages crizotinib-resistant NPM-ALK(+) cell growth. J Clin Invest. 2015;125(9):3505-18. doi: 10.1172/JCI78488.
53. de Yebenes VG, Belver L, Pisano DG, et al. MiR-181b negatively regulates activation-induced cytidine deaminase in B cells. J Exp Med. 2008;205(10):2199-206. doi: 10.1084/jem.20080579.
54. Xu X, Ge S, Jia R, et al. Hypoxia-induced miR-181b enhances angiogenesis of retinoblastoma cells by targeting PDCD10 and GATA6. Oncol Rep. 2015;33(6):2789-96. doi: 10.3892/or.2015.3900.
55. Mraz M, Chen L, Rassenti LZ, et al. MiR-150 infl uences B-cell receptor signaling in chronic lymphocytic leukemia by regulating expression of GAB1 and FOXP1. Blood. 2014;124(1):84-95. doi: 10.1182/blood-2013-09-527234.
56. Manoharan P, Basford JE, Pilcher-Roberts R, et al. Reduced levels of microRNAs miR-124a and miR-150 are associated with increased proinfl ammatory mediator expression in Kruppellike factor 2 (KLF2)-deficient macrophages. J Biol Chem. 2014;289(45):31638-46. doi: 10.1074/jbc.M114.579763.
57. Zhou B, Wang S, Mayr C, et al. MiR-150, a microRNA expressed in mature B and T cells, blocks early B cell development when expressed prematurely. Proc Natl Acad Sci U S A. 2007;104(17):7080-5. doi: 10.1073/pnas.0702409104.
58. Dorsett Y, McBride KM, Jankovic M, et al. MicroRNA-155 suppresses activation-induced cytidine deaminase-mediated Myc-Igh translocation. Immunity. 2008;28(5):630-8. doi: 10.1016/j.immuni.2008.04.002.
59. Wang YZ, Tian FF, Yan M, et al. Delivery of an miR155 inhibitor by anti-CD20 single-chain antibody into B cells reduces the acetylcholine receptor-specific autoantibodies and ameliorates experimental autoimmune myasthenia gravis. Clin Exp Immunol. 2014;176(2):207-21. doi: 10.1111/cei.12265.
60. Neilsen PM, Noll JE, Mattiske S, et al. Mutant p53 drives invasion in breast tumors through up-regulation of miR-155. Oncogene. 2013;32(24):2992-3000. doi: 10.1038/onc.2012.305.
61. Yin Q, Wang X, McBride J, et al. B-cell receptor activation induces BIC/miR-155 expression through a conserved AP-1 element. J Biol Chem. 2008;283(5):2654-62. doi: 10.1074/jbc.M708218200.
62. Carpenter S, Aiello D, Atianand MK, et al. A long non-coding RNA mediates both activation and repression of immune response genes. Science. 2013;341(6147):789-92. doi: 10.1126/science.1240925.
63. Krawczyk M, Emerson BM. P50-associated COX-2 extragenic RNA (PACER) activates COX-2 gene expression by occluding repressive NF-kappaB complexes. Elife. 2014;3:e1776.
64. Liu B, Sun L, Liu Q, et al. A cytoplasmic NF-kappaB interacting long non-coding RNA blocks IkappaB phosphorylation and suppresses breast cancer metastasis. Cancer Cell. 2015;27(3):370-81. doi: 10.1016/j.ccell.2015.02.004.
65. Wang P, Xue Y, Han Y, et al. The STAT3-binding long non-coding RNA lnc-DC controls human dendritic cell differentiation. Science. 2014;344(6181):310-13. doi: 10.1126/science.1251456.
66. Cui H, Xie N, Tan Z, et al. The human long non-coding RNA lnc-IL7R regulates the infl ammatory response. Eur J Immunol. 2014;44(7):2085-95. doi: 10.1002/eji.201344126.
67. Rapicavoli NA, Qu K, Zhang J, et al. A mammalian pseudogene lncRNA at the interface of infl ammation and anti-infl ammatory therapeutics. Elife. 2013;2:e762. doi: 10.7554/eLife.00762.
68. Collier SP, Henderson MA, Tossberg JT, Aune TM. Regulation of the th1 genomic locus from ifng through tmevpg1 by t-bet. J Immunol. 2014;193(8):3959-65. doi: 10.4049/jimmunol.1401099.
69. Gomez JA, Wapinski OL, Yang YW, et al. The NeST long ncRNA controls microbial susceptibility and epigenetic activation of the interferon-γ locus. Cell. 2013;152(4):743-54. doi: 10.1016/j.cell.2013.01.015.
70. Hu G, Tang Q, Sharma S, et al. Expression and regulation of intergenic long non-coding RNAs during T cell development and differentiation. Nat Immunol. 2013;14(11):1190-8. doi: 10.1038/ni.2712.
71. Zhang H, Nestor CE, Zhao S, et al. Profiling of human CD4+ T-cell subsets identifies the TH2-specific non-coding RNA GATA3-AS1. J Allergy Clin Immunol. 2013;132(4):1005-8. doi: 10.1016/j.jaci.2013.05.033.
72. Hwang SS, Kim K, Lee W, Lee GR. Aberrant expression of IFN-gamma in Th2 cells from Th2 LCR-deficient mice. Biochem Biophys Res Commun. 2012;424(3):512-18. doi: 10.1016/j.bbrc.2012.06.146.
73. Spurlock CF, Tossberg JT, Guo Y, et al. Expression and functions of long non-coding RNAs during human T helper cell differentiation. Nat Commun. 2015;6:6932. doi: 10.1038/ncomms7932.
74. Ranzani V, Rossetti G, Panzeri I, et al. The long intergenic non-coding RNA landscape of human lymphocytes highlights the regulation of T cell differentiation by linc-MAF-4. Nat Immunol. 2015;16(3):318-25. doi: 10.1038/ni.3093.
75. Sharma S, Findlay GM, Bandukwala HS, et al. Dephosphorylation of the nuclear factor of activated T cells (NFAT) transcription factor is regulated by an RNA-protein scaffold complex. Proc Natl Acad Sci U S A. 2011;108(28):11381-6. doi: 10.1073/pnas.1019711108.
76. Sehgal L, Mathur R, Braun FK, et al. FAS-antisense 1 lncRNA and production of soluble versus membrane Fas in B-cell lymphoma. Leukemia. 2014;28(12):2376-87. doi: 10.1038/leu.2014.126.